Go Pro
OTCMKTS:BICX

Biocorrx Q4 2025 Earnings Report

Biocorrx logo
$0.23 -0.01 (-5.13%)
As of 08/19/2026 09:30 AM Eastern

Biocorrx EPS Results

Actual EPS
$0.05
Consensus EPS
-$0.06
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Biocorrx Revenue Results

Actual Revenue
($0.15) million
Expected Revenue
$0.22 million
Beat/Miss
Missed by -$370.00 thousand
YoY Revenue Growth
N/A

Biocorrx Announcement Details

Quarter
Q4 2025
Time
During Market Hours
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Biocorrx Earnings Headlines

Biocorrx Inc. (OTCMKTS:BICX) Short Interest Update
BioCorRx Inc.
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.tc pixel
See More Biocorrx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biocorrx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biocorrx and other key companies, straight to your email.

About Biocorrx

Biocorrx (OTCMKTS:BICX), through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

View Biocorrx Profile